Navigation Links
Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
Date:12/4/2009

SEATTLE Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins may protect stem cell transplant patients from one of the most serious complications of the life-saving cancer therapy: graft-versus-host disease, or GVHD. The findings are reported in the Nov. 4 first edition of the journal Blood.

In a retrospective study of 567 patients who underwent hematopoietic cell transplantation from matched sibling donors between 2001 and 2007, patients whose donors had been taking statins at the time of stem cell donation experienced no severe acute GVHD. About 15 percent of the stem cell donors in the study were taking statins at the time of transplant.

Normally, between 10 percent and 15 percent of transplant patients would be expected to develop severe acute GVHD, according to the study's senior author Marco Mielcarek, M.D., an assistant member of the Hutchinson Center's Clinical Research Division.

No such protection from severe acute GVHD was observed if only the patient was taking a statin, according to the study. There was some indication that protection against severe GVHD was even stronger when both patient and donor had been on statin medications, however the number of patients in this group was too small to be statistically significant.

The researchers also found that only those transplant patients with statin-treated donors who received cyclosporine-based immunosuppression therapy after transplantation were protected from severe GVHD. Patients with statin-treated donors who received a similar drug, tacrolimus, did not experience the same GVHD-protection. The study also found that the greatest statin protection occurred against severe GVHD of the gastrointestinal tract.

GVHD is a common side effect in patients who receive blood stem cell transplants from related or unrelated donors. It occurs when the transplanted cells recognize the recipient's tissues as foreign and attack the tissues. This can cause a variety of problems, including skin rashes, diarrhea and liver inflammation. Acute GVHD often occurs in the first three months after a transplant and can lead to mortality as high as 50 percent if it is severe. It can be deadly because patients require more immunosuppressive drugs to treat it, which can trigger a cascade of complications such as secondary infections.

Mielcarek, first author Marcello Rotta, M.D., a postdoctoral research fellow in the Hutchinson Center's Clinical Research Division, and colleagues undertook the study because previous research showed that statins have anti-inflammatory effects and have been found to improve control of other inflammatory diseases such as rheumatoid arthritis. Recently, studies using mouse models of stem cell transplantation have shown protection against lethal acute GVHD when the donors and recipients had been treated with statins before transplant.

The exact mechanism of how statins protect against GVHD is not known.

"In the literature, a multitude of possible mechanisms are discussed by which statins may influence immune function," Mielcarek said. "One is cell adhesion the stickiness of cells that influences how donor T cells that cause GVHD can migrate to certain target tissues. Another is how statins interfere with intracellular signaling in T cells. Statins may dampen the activity of allo-reactive T cells and prevent them from initiating the inflammatory cascade that's required to cause GVHD."

Grants from the National Institutes of Health and The Dana Foundation funded this research.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Cholesterol-lowering medicines may be effective against cancer
2. Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications
3. Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known
4. Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research
5. Study shows cholesterol-lowering power of dietitian visits
6. Cholesterol-Lowering Statins Tied to Tendon Woes
7. Cholesterol-Lowering Drugs May Ease Irregular Heartbeat
8. New Type of Cholesterol-Lowering Drug Shows Promise
9. Many Patients Stop Taking Cholesterol-Lowering Drugs
10. Cholesterol-lowering drug linked to sleep disruptions
11. Diabetes Drugs Go Head-to-Head in Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... Business Journalists , led by the Wharton School’s most prominent professors, help ... one-day program at the Wharton School’s San Francisco campus will feature Wharton ...
(Date:5/5/2016)... ... 05, 2016 , ... Derrin Doty Group has unveiled the latest charity campaign ... communities west of Seattle. The insurance provider’s caring team has been so moved by ... due to complications from the flu, that they have decided to extend their original ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/5/2016)... ... May 05, 2016 , ... Long Island’s fastest growing comprehensive eye care ... Island eye surgeon, Kathleen Van Valkenburg, MD as part of their ongoing effort to ... medical director and managing partner of North Shore Eye Care. , “We are ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade students ... , Director of Allergy and Asthma Clinical Research in the Division of Pulmonary, ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Systemic Lupus Erythematosus ...  report to their offering.       ... The latest research Europe Systemic Lupus Erythematosus ... provides comprehensive insights into Systemic Lupus Erythematosus ...
(Date:5/4/2016)... an upgrade. There are many medical recorders on the market but none like this. ... HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
Breaking Medicine Technology: